PROSTATE-SPECIFIC ANTIGEN AND ITS MOLECULAR FORMS IN BLOOD SERUM OF HEALTHY WOMEN AND WOMEN WITH BREAST DISEASE
N. S. Sergeeva,
I. I. Alentov,
D. R. Ortabaeva,
N. V. Marshutina,
A. D. Zikiryahodzhaev,
A. D. Kaprin https://doi.org/10.21294/1814-4861-2019-18-6-96-104
Abstract
The purpose of the study was to provide data on the sources of prostate-specific antigen (Psa) in women, as well as on serum Psa levels in healthy women and in women with benign and malignant breast cancer. Material and methods. We analyzed 50 publications available from PubMed, Medline, Google scholar concerning non-prostatic sources of Psa and its use as a serum tumor-associated marker for benign and malignant breast tumors. Results. In our study, we focus on the recent findings on non-prostatic sources and regulation of Psa synthesis in women as well as on changes in serum concentrations of this marker in patients with benign and malignant breast tumors. Various Psa isoforms (total Psa and free Psa) and free/total ratio for the detection of breast cancer and the assessment of treatment response and early detection of breast cancer recurrence were analyzed. Conclusion. the results obtained highlight the value of the assessment of Psa isoforms for early detection, prediction of therapy response and detection of breast cancer relapse. However, further studies are needed to identify the role of Psa isoforms in the diagnosis and monitoring of breast cancer patients.
About the Authors
N. S. Sergeeva
P.А. Gertsen Moscow Research Institute of Oncology – branch of Federal Medical Research Radiology Center; Biology Department,
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Professor, Head of the Department of Therapy Response Prediction
Author ID (Scopus): 7102748586
3, 2-nd Botkinsky Proezd, 125284-Moscow, Russia
1, Ostrovityanova street, 117997-Moscow, Russia
I. I. Alentov
P.А. Gertsen Moscow Research Institute of Oncology – branch of Federal Medical Research Radiology Center
Russian Federation
Russian Federation
PhD, Researcher, Department of Therapy Response Prediction
3, 2-nd Botkinsky Proezd, 125284-Moscow, Russia
D. R. Ortabaeva
P.А. Gertsen Moscow Research Institute of Oncology – branch of Federal Medical Research Radiology Center
Russian Federation
Russian Federation
MD, surgeon, oncologist, General Clinic Department
Researcher ID (WOS): Y-6369-2018
3, 2-nd Botkinsky Proezd, 125284-Moscow, Russia
N. V. Marshutina
P.А. Gertsen Moscow Research Institute of Oncology – branch of Federal Medical Research Radiology Center
Russian Federation
Russian Federation
PhD, Senior Researcher, Department of Therapy Response Prediction
3, 2-nd Botkinsky Proezd, 125284-Moscow, Russia
A. D. Zikiryahodzhaev
P.А. Gertsen Moscow Research Institute of Oncology – branch of Federal Medical Research Radiology Center,
RUDN University
Russian Federation
Russian Federation
MD, Professor, Head of Department of Oncology and Reconstructive Plastic Surgery of Breast and Skin; Department of Oncology and Radiology
3, 2-nd Botkinsky Proezd, 125284-Moscow, Russia
A. D. Kaprin
P.А. Gertsen Moscow Research Institute of Oncology – branch of Federal Medical Research
Radiology Center
Russian Federation
Russian Federation
MD, Professor, Head
Author ID (Scopus): 6602709853
3, 2-nd Botkinsky Proezd, 125284-Moscow, Russia
References
1. Li T.S., Behrman S.J. The sperm- and seminal plasma-specific antigens of human semen. Fertil Steril. 1970 Jul; 21(7): 565–73. doi: 10.1016/s0015-0282(16)37627-0.
2. Shulman S., Bronson P. Immunochemical studies on human seminal plasma. II. The major antigens and their fractionation. J Reprod Fertil. 1969 Apr; 18(3): 481–91. doi: 10.1530/jrf.0.0180481.
3. Hara M., Koyanagi Y., Inoue T., Fukuyama T. Some physico-сhemical characteristics of “-seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi. 1971 Jul; 25(4): 322–4.
4. Ablin R.J., Bronson P., Soanes W.A., Witebsky E. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol. 1970; 104(6): 1329–39.
5. Papsidero L.D., Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980 Jul; 40(7): 2428–32.
6. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8; 317(15): 909–16. doi: 10.1056/NEJM198710083171501.
7. Lilja H., Oldbring J., Rannevik G., Laurell C.B. Seminal vesiclesecreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987 Aug; 80(2): 281–5. doi: 10.1172/JCI113070.
8. Kumar A., Mikolajczyk S.D., Goel A.S., Millar L.S., Saedi M.S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997; 57(15): 3111–4.
9. Mikolajczyk S.D., Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 2003 Jun; 52(2): 86–91.
10. Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology. 2002 Jun; 59(6): 797–802. doi: 10.1016/s0090-4295(01)01605-3.
11. Pérez-Ibave D.C., Burciaga-Flores C.H., Elizondo-Riojas M.Á. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. Cancer Epidemiol. 2018; 54: 48–55. doi: 10.1016/j.canep.2018.03.009.
12. Gittes R.F., Nakamura R.M. Female urethral syndrome. A female prostatitis? West J Med. 1996 May; 164(5): 435–8.
13. Wernert N., Albrech M., Sesterhenn I., Goebbels R., Bonkhoff H., Seitz G., Inniger R., Remberger K. The ‘female prostate’: location, morphology, immunohistochemical characteristics and significance. Eur Urol. 1992; 22(1): 64–9. doi: 10.1159/000474724.
14. Dodson M.K., Cliby W.A., Keeney G.L., Peterson M.F., Podratz K.C. Skene’s gland adenocarcinoma with increased serum level of prostatespecific antigen. Gynecol Oncol. 1994 Nov; 55(2): 304–7. doi: 10.1006/gyno.1994.1294.
15. Mannello F., Gazzanelli G. Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res. 2001; 3(4): 238–43.
16. Yu H., Diamandis E.P. Prostate-specific antigen in milk of lactating women. Clin Chem. 1995 Jan; 41(1): 54–8.
17. Yu H., Diamandis E.P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C.M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996; 40(2): 171–8. doi: 10.1007/bf01806212.
18. Mannello F., Sebastiani M., Amati S., Gazzanelli G. Prostatespecific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys. Clin Chem. 1997 Aug; 43(8 Pt1): 1448–54.
19. Clements J., Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994 Jun; 78(6): 1536–9. doi: 10.1210/jcem.78.6.7515392.
20. Melegos D.N., Yu H., Allen L.C., Diamandis E.P. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem. 1996 Dec; 29(6): 555–62. doi: 10.1016/s0009-120(96)00093-8.
21. Yu H., Diamandis E.P. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem. 1995 Feb; 41(2): 204–10.
22. Olsson A.Y., Bjartell A., Lilja H., Lundwall A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer. 2005 Jan 10; 113(2): 290–7. doi: 10.1002/ijc.20605.
23. Pezzilli R., Bertaccini A., Billi P., Zanarini L., Miglio F., Martorana G. Serum prostate-specific antigen in pancreatic disease. Ital J Gastroenterol Hepatol. 1999 Oct; 31(7): 580–3.
24. Smith M.R., Biggar S., Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res. 1995 Jun 15; 55(12): 2640–4.
25. Melegos D.N., Yu H., Ashok M., Wang C., Stanczyk F., Diamandis E.P. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab. 1997 Mar; 82(3): 777–80. doi: 10.1210/jcem.82.3.3792.
26. Figueroa C.D., Molina L., Bhoola K.D., Ehrenfeld P. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer. Biol Chem. 2018 Sep 25; 399(9): 937–957. doi: 10.1515/hsz-2018-0111.
27. Chan D.W., Booth A.R., Diamandis E.P. Tietz text book of clinical chemistry and molecular diagnostics. 4th rev. St. Louis, USA: Elsevier Saunders, 2006. 2412 p.
28. Razavi S.H., Ghajarzadeh M., Abdollahi A., Shoar S., Omranipour R. Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women? Int J Prev Med. 2015 Feb 20; 6: 15. doi: 10.4103/2008-7802.151824.
29. Zarghami N., Grass L., Sauter E.R., Diamandis E.P. Prostatespecific antigen in serum during the menstrual cycle. Clin Chem. 1997 Oct; 43(10): 1862–7.
30. Nagar R., Msalati A.A. Changes in Serum PSA During Normal Menstrual Cycle. Indian J Clin Biochem. 2013 Jan; 28(1): 84–9. doi: 10.1007/s12291-012-0263-2.
31. Aksoy H., Akçay F., Umudum Z., Yildirim A.K., Memisogullari R. Changes of PSA concentrations in serum and saliva of healthy women during the menstrual cycle. Ann Clin Lab Sci. 2002 Winter; 32(1): 31–6.
32. Mannello F., Bianchi G., Gazzanelli G. Immunoreactivity of prostate-specific antigen in plasma and saliva of healthy women. Clin Chem. 1996 Jul; 42(7): 1110–1.
33. Burelli A., Cionini R., Rinaldi E., Benelli E., Fiore E., Canale D., Bencivelli W., Nencetti C., Pinchera A., Pucci E. Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome. J Endocrinol Invest. 2006 Apr; 29(4): 308–12. doi: 10.1007/BF03344101.
34. Musrap N., Diamandis E.P. Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. Clin Chem. 2016 Aug; 62(8): 1066–74. doi: 10.1373/clinchem.2016.256198.
35. Bili E., Dampala K., Iakovou I., Tsolakidis D., Giannakou A., Tarlatzis B.C. The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). Eur J Obstet Gynecol Reprod Biol. 2014 Aug; 179: 32–5. doi: 10.1016/j.ejogrb.2014.05.006.
36. Negri C., Tosi F., Dorizzi R., Fortunato A., Spiazzi G.G., Muggeo M., Castello R., Moghetti P. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000 Jan; 85(1): 81–4. doi: 10.1210/jcem.85.1.6230.
37. Yu H., Diamandis E.P., Sutherland D.J. Immunoreactive prostatespecific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem. 1994 Apr; 27(2): 75–9. doi: 10.1016/0009-9120(94)90015-9.
38. Borchert G.H., Melegos D.N., Tomlinson G., Giai M., Roagna R., Ponzone R., Sgro L., Diamandis E.P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997; 76(8): 1087–94. doi: 10.1038/bjc.1997.512.
39. Borchert G., Giai M., Diamandis E.P. Elevated levels of prostate specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst. 1997; 89: 587–8. doi: 10.1093/jnci/89.8.587.
40. Radowicki S., Kunicki M., Bandurska-Stankiewicz E. Prostatespecific antigen in the serum of women with benign breast disease. Eur J Obstet Gynecol Reprod Biol. 2008; 138(2): 212–6. doi: 10.1016/j.ejogrb.2007.05.023.
41. Black M.H., Giai M., Ponzone R., Sismondi P., Yu H., Diamandis E.P. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res. 2000 Feb; 6(2): 467–73.
42. Dash P., Pati S., Mangaraj M., Sahu P.K., Mohapatra P.C. Serum total PSA and free PSA in breast tumors. Indian J Clin Biochem. 2011 Apr; 26(2): 182–6. doi: 10.1007/s12291-011-0115-5.
43. Das S., Paul R., De U., Mukhopadhyay M. The lady with raised prostate specific antigen: do we need to worry? Asian Pac J Cancer Prev. 2011; 12(8): 2051–3.
44. Romppanen J., Keskikuru R., Kataja V., Eskelinen M., Kosma V.M., Savolainen K., Uusitupa M., Mononen I. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer. 1999 Mar; 79(9–10): 1583–7. doi: 10.1038/sj.bjc.6690252.
45. Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M.A., Diamandis E.P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep; 72(3): 728–31. doi: 10.1038/bjc.1995.401.
46. Mashkoor F.C., Al-Asadi J.N., Al-Naama L.M. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 2013 Oct; 37(5): 613–8. doi: 10.1016/j.canep.2013.06.009.
47. Jahir E.T., Devi R., Borthakur B.B. Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. J Clin Diagn Res. 2017 Mar; 11(3): BC13BC16. doi: 10.7860/JCDR/2017/22111.9543.
48. Usoro A.J., Udoh A.E., Usoro C.A.O., Etuk E.B., Obot A.S. Evaluation of serum levels of mammaglobin, carcinoembryonic antigen, prolactin, estradiol and free prostate specific antigen as biomarkers of breast cancer. J Global Oncol. 2018; 4(2): 34. doi: 10.1200/jgo.18.14300.
49. Zhang L., Yu X., Zhou L., Yang Y., Liu S. Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era. J BUON. 2018 Sep-Oct; 23(5): 1316–1324.
50. Melegos D.N., Diamandis E.P. Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem. 1996 Jun; 29(3): 193–200. doi: 10.1016/0009-9120(96)00014-e.
51. Li H.F., Xie Q., Nie Q.W., Ye X. Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study. Eur Rev Med Pharmacol Sci. 2018 Jul; 22(13): 4188–4195. doi: 10.26355/eurrev_201807_15412.
52. Webber M.M., Waghray A., Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995 Oct; 1(10): 1089–94.
53. Cohen P., Peehl D.M., Graves H.C., Rosenfeld R.G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994 Sep; 142(3): 407–15. doi: 10.1677/joe.0.1420407.
54. Gill Z.P., Perks C.M., Newcomb P.V., Holly J.M. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 1997 Oct 10; 272(41): 25602–7. doi: 10.1074/jbc.272.41.25602.
55. Hanamura T., Ohno K., Houkibara S., Murasawa H., Nakamura T., Watanabe H., Kaizuka M., Sawano S., Koyama H., Ito K. Clinical significance of serum PSA in breast cancer patients. Cancer Research. 2019 Feb; 79(4): 1–23. doi: 10.1158/1538-7445.SABCS18-P4-01-23.
56. Yu H., Giai M., Diamandis E.P., Katsaros D., Sutherland D.J., Levesque M.A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15; 55(10): 2104–10.
Review
For citations:
Sergeeva N.S., Alentov I.I., Ortabaeva D.R., Marshutina N.V., Zikiryahodzhaev A.D., Kaprin A.D. PROSTATE-SPECIFIC ANTIGEN AND ITS MOLECULAR FORMS IN BLOOD SERUM OF HEALTHY WOMEN AND WOMEN WITH BREAST DISEASE. Siberian journal of oncology. 2019;18(6):96-104. (In Russ.) https://doi.org/10.21294/1814-4861-2019-18-6-96-104
Views:
9006
Email this article 
